[
  {
    "question": "Typical scenario of pt came with decreased sensation and bilateral weakness in LL with areflexia. Pt had a history of diarrhea 10 days back. What is the diagnosis??",
    "option_a": "AIDP",
    "option_b": "CIDP",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy) is the most common variant of Guillain\u2013Barr\u00e9 syndrome (GBS). It typically presents with rapidly progressive, symmetrical weakness, usually beginning in the lower limbs, and is accompanied by areflexia. A preceding infectious event \u2013 often diarrhea due to Campylobacter jejuni \u2013 is a classic historical clue. The disorder is believed to result from an immune-mediated attack on peripheral nerve myelin. Molecular mimicry between microbial antigens and peripheral nerve components leads to demyelination. Recent studies have further confirmed the role of autoimmune mechanisms with complement activation and macrophage infiltration in the nerve roots and peripheral nerves. Patients present with an ascending pattern of weakness often beginning in the legs, along with sensory changes such as decreased sensation. The loss of deep tendon reflexes (areflexia) is a hallmark. The history of diarrhea about 10 days prior fits well with the typical post\u2010infectious onset of GBS. Diagnosis involves a combination of clinical history, neurological examination, cerebrospinal fluid (CSF) analysis (which may show albuminocytological dissociation), and nerve conduction studies revealing demyelination. Differential diagnoses include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), spinal cord lesions, and metabolic neuropathies; the acute time course and postinfectious history help differentiate AIDP from these conditions. The first-line treatments are intravenous immunoglobulin (IVIG) and plasmapheresis. Early supportive care and monitoring of respiratory function are essential. In pregnancy and lactation, IVIG is generally considered safe and is the preferred modality; plasmapheresis can be used with appropriate expertise if needed. Option A (AIDP) is correct, as it best fits the clinical scenario. Option B (CIDP) is incorrect because CIDP has a more insidious onset and chronic course, unlike the acute postinfectious picture described. 1. A history of diarrhea preceding neurological deficits is a red flag for postinfectious GBS. 2. Areflexia in the context of symmetrical ascending weakness is highly suggestive of AIDP. 3. Early initiation of immunotherapy can improve outcomes significantly. Recent guidelines emphasize early recognition and treatment of GBS using IVIG or plasmapheresis. Studies continue to refine prognostic indicators and highlight the safety of IVIG in special populations including pregnant women.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Female Patient complaining of diplopia and ptosis fluctuating ?",
    "option_a": "Ocular MG",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Ocular Myasthenia Gravis (MG) is a form of an autoimmune neuromuscular junction disorder primarily affecting the extraocular muscles, resulting in symptoms like diplopia and ptosis. The fluctuating nature of the symptoms is considered a hallmark of MG. MG results from autoantibodies (often against the acetylcholine receptor or MuSK) that impair neuromuscular transmission. This immune-mediated blockade leads to muscle fatigue and weakness that increases with repetitive use and improves with rest. Patients, particularly females, often present with fluctuating ptosis (eyelid drooping) and diplopia (double vision). Symptoms can vary over the course of the day \u2013 with worsening at the end of the day \u2013 which is a key clinical clue. Diagnosis is established by clinical features, serological testing for acetylcholine receptor (AChR) and anti-MuSK antibodies, and electrophysiologic studies such as repetitive nerve stimulation or single-fiber electromyography. Differential diagnoses include cranial nerve palsies, brainstem lesions, and neuromuscular junction disorders such as LEMS. The fluctuating nature distinguishes MG from fixed neurological deficits. First-line treatment for ocular MG typically includes acetylcholinesterase inhibitors such as pyridostigmine. If symptoms persist or worsen, immunosuppressive therapy such as corticosteroids or steroid-sparing agents may be added. In pregnancy, pyridostigmine is considered relatively safe, and immunosuppressants are used judiciously in lactating mothers after weighing risks versus benefits. Option A (Ocular MG) is correct, given the classical description of fluctuating diplopia and ptosis. Other options, if present, would likely not capture the fluctuating nature or the typical clinical presentation of MG. 1. Fluctuating symptoms with diurnal variation are key for suspecting MG. 2. Ocular involvement is often the first manifestation of myasthenia gravis. 3. Early serologic testing and electrophysiologic studies are critical for diagnosis. Current research supports the use of acetylcholinesterase inhibitors and highlights the importance of antibody testing in guiding therapy. Updated guidelines also stress tailored immunosuppression strategies, particularly in women of childbearing age.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Young Patient with proximal painful weakness, I think there was biopsy result (CD+8) !!!",
    "option_a": "Polymyositis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Polymyositis is an idiopathic inflammatory myopathy classically presenting with symmetric, proximal muscle weakness. The condition is immune-mediated and often presents in younger individuals with painless or sometimes mildly painful weakness. The pathologic hallmark of polymyositis is the presence of endomysial inflammatory infiltrates predominantly composed of CD8+ T lymphocytes that invade and destroy muscle fibers. This cell-mediated process leads to muscle fiber necrosis and subsequent weakness. Patients typically report difficulty in performing activities that require the use of proximal muscles, such as rising from a chair or climbing stairs. Although pain is not always prominent in polymyositis, some patients may report muscle discomfort. The mention of a biopsy with CD8+ cells strongly supports a diagnosis of polymyositis over other inflammatory myopathies. Diagnosis is based on clinical evaluation, elevated muscle enzymes (especially creatine kinase), electromyography showing myopathic changes, and confirmation via muscle biopsy demonstrating endomysial inflammatory infiltrates with CD8+ T cells. Differential diagnoses include dermatomyositis (which has distinctive skin findings and a different immune cell profile), inclusion body myositis (typically seen in older patients with both proximal and distal weakness), and metabolic myopathies. The first-line treatment is high-dose corticosteroids (e.g., prednisone). If patients do not respond adequately, steroid-sparing immunosuppressants such as methotrexate or azathioprine are considered. In pregnant or lactating patients, corticosteroids (preferably prednisone due to its low placental transfer) remain the mainstay of treatment, with careful monitoring of both mother and fetus/infant. Option A (Polymyositis) is correct given the clinical presentation of proximal muscle weakness and the biopsy finding of CD8+ lymphocytes. Other potential options would not explain the biopsy findings or the clinical syndrome as accurately. 1. Symmetrical proximal muscle weakness with elevated CK levels is highly suggestive of an inflammatory myopathy. 2. Muscle biopsy showing CD8+ T cell infiltration is pathognomonic for polymyositis. 3. Early treatment with steroids can help prevent irreversible muscle damage. Recent guidelines advocate early initiation of high-dose corticosteroids for polymyositis and support the use of steroid-sparing agents to reduce long-term side effects. There is ongoing research to refine immunomodulatory treatment protocols to improve patient outcomes.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Case about gasterman syndrome",
    "option_a": "",
    "option_b": ") is incorrect because the extensive option analysis provided emphasizes that there is no clearly defined correct choice for this case. The analysis reviews reasons against each potential differential (MG, LEMS, CMS, and Botulism) without confirming a diagnosis of 'Gasterman syndrome.' This reflects the current diagnostic uncertainty.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "N/A",
    "subspecialty": "Neuromuscular",
    "explanation": "The case refers to 'Gasterman syndrome', a term that is not well established in current neurology literature. There is uncertainty and confusion surrounding its definition, and it appears to be either a very rare entity or a misnomer that may have been confused with other, better\u2010defined conditions. Due to the rarity and incomplete characterization of Gasterman syndrome, a clear pathophysiologic mechanism has not been elucidated. The provided option analysis discusses differential diagnoses primarily within the spectrum of neuromuscular junction disorders, emphasizing the absence of a distinct mechanism corresponding to this syndrome. The clinical features remain uncertain, and the case analysis instead focuses on distinguishing among conditions like Myasthenia Gravis, Lambert\u2013Eaton Myasthenic Syndrome, Congenital Myasthenic Syndromes, and Botulism based on classical features. Without a defined clinical picture for Gasterman syndrome, its identification remains a diagnostic challenge. In scenarios where a rare or poorly characterized syndrome is suspected, a broad diagnostic work-up is undertaken. This includes antibody testing (for MG and LEMS), electrophysiological studies, and possibly genetic testing for congenital forms. The differential diagnosis also involves careful history-taking regarding toxin exposure in cases like botulism. The lack of concrete diagnostic criteria for Gasterman syndrome precludes a definitive diagnosis. In the absence of clearly defined diagnostic criteria, management would be largely empirical and supportive. For conditions in the differential \u2013 such as MG or LEMS \u2013 treatment involves acetylcholinesterase inhibitors, immunomodulatory therapies, or symptomatic management. In pregnancy and lactation, treatment decisions would follow guidelines for the more clearly defined conditions, with an emphasis on therapies known to be safe in these populations. The marked answer (Option B) is incorrect because the extensive option analysis provided emphasizes that there is no clearly defined correct choice for this case. The analysis reviews reasons against each potential differential (MG, LEMS, CMS, and Botulism) without confirming a diagnosis of 'Gasterman syndrome.' This reflects the current diagnostic uncertainty. 1. A diagnosis should not be made when a syndrome is poorly characterized in the literature. 2. When faced with diagnostic uncertainty, it is essential to carefully rule out more common and well-defined conditions. 3. Always correlate clinical findings with established diagnostic criteria before labeling a patient with a rare syndrome. Recent literature and guidelines call for further research into rare and ill-defined syndromes. The lack of specific evidence for 'Gasterman syndrome' underscores the need for cautious interpretation and reliance on established diagnostic frameworks for neuromuscular disorders.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient on long-term use of colchicine, developed myopathy and neuropathy (I don\u2019t remember the scenario)!!",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Neuromuscular",
    "explanation": "Colchicine is an anti\u2010inflammatory agent that, when used long term, can produce a distinct neuromyopathy. Its toxicity is characterized by a combined myopathy and neuropathy with typical vacuolar changes seen on muscle biopsy. This entity is distinct from other forms of myopathy such as inflammatory or hereditary types. Colchicine binds tubulin and disrupts microtubule polymerization, impairing intracellular transport. This disruption leads to accumulation of autophagic vacuoles in muscle fibers and interferes with axonal transport, resulting in both myopathic and neuropathic changes. These effects are dose\u2010 and duration\u2010dependent, especially in patients with renal impairment or drug interactions that elevate colchicine levels. Patients present with proximal muscle weakness, often accompanied by distal paresthesias or neuropathic pain. The temporal association with long\u2010term colchicine use (commonly for gout or familial Mediterranean fever) and the absence of inflammatory markers distinguishes it from inflammatory myopathies. The differential diagnosis includes inflammatory myopathies (e.g., polymyositis), hereditary neuropathies (such as Charcot-Marie-Tooth disease), and other drug-induced myopathies (e.g., from statins). A careful history, laboratory evaluation (including CK levels), electromyography, and muscle biopsy (revealing vacuolar changes without significant inflammation) help establish the diagnosis of colchicine-induced toxicity. The first-line management is immediate cessation of colchicine to prevent further neuromuscular damage. Supportive care including physical therapy is recommended. In cases where colchicine is essential (such as in certain familial periodic fever syndromes), dose adjustments or alternative therapies should be considered. In pregnant or lactating patients, the risks of colchicine toxicity necessitate careful consideration, with preference for the safest alternative available per current guidelines. Although potential answer choices might have included inflammatory myopathy, hereditary neuropathy, or other drug-induced neuropathies, none completely explain the clinical scenario. The key discriminating features\u2014temporal association with colchicine use and the vacuolar changes on biopsy\u2014point directly to colchicine toxicity. Therefore, 'None' (i.e., none of the alternative options is correct) is the appropriate answer. 1) Always assess colchicine dose and renal function in long-term users to prevent toxicity. 2) Vacuolar changes on muscle biopsy are a hallmark of colchicine-induced myopathy. 3) Early recognition and drug cessation can reverse or improve symptoms. Recent studies underscore the importance of monitoring patients on long-term colchicine, particularly those with renal impairment. Current literature reinforces that colchicine's mechanism\u2014microtubule disruption\u2014leads to a toxic myopathy/neuropathy that is reversible upon prompt cessation of the drug.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Female pt k/c of MG with no improvement in her symptoms she had thymus hyperplasia (grade: 4), what to do for management :",
    "option_a": "Thymus removal",
    "option_b": "steroid",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia gravis (MG) is an autoimmune disorder characterized by antibodies that disrupt neuromuscular transmission. The thymus plays a key role in the pathogenesis, where thymic hyperplasia (and thymoma in some cases) is commonly noted, particularly in younger patients. Thymic hyperplasia leads to abnormal T-cell education and may contribute to the generation of pathogenic autoantibodies against the acetylcholine receptor. Removal of the abnormal thymic tissue reduces the autoimmune drive, which often translates into improved clinical outcomes. Patients with MG typically present with fatigable muscle weakness that may involve ocular, bulbar, and limb muscles. In patients with significant thymic hyperplasia (as noted by a high-grade finding), thymectomy is indicated, particularly when medical management alone does not yield sufficient improvement. The diagnosis of MG is confirmed via serologic tests (anti\u2013acetylcholine receptor antibodies or anti\u2013MuSK antibodies), electrophysiological studies (repetitive nerve stimulation), and imaging (CT/MRI of the thymus). Differential diagnoses include congenital myasthenic syndromes and Lambert-Eaton syndrome, which can be distinguished by specific clinical and electrophysiological criteria. First-line therapy for MG includes acetylcholinesterase inhibitors and immunosuppressive therapies. In patients with thymic hyperplasia, thymectomy is recommended and has been shown to improve long-term outcomes, as demonstrated in the MGTX trial. In pregnant patients, thymectomy is typically deferred to the postpartum period if possible, whereas careful use of immunosuppressants (with considerations for fetal safety) is warranted. Option A (thymus removal) is the appropriate management strategy in a patient with MG who demonstrates significant thymic hyperplasia (grade 4) and shows poor response to medical therapy. While steroids (Option B) are an important component of immunosuppressive therapy, they are generally used adjunctively when thymic pathology is present and not as the sole treatment modality. 1) Thymic pathology is a key determinant in the management of MG and can inform the decision for thymectomy. 2) The MGTX trial provides evidence supporting thymectomy in non-thymomatous MG with thymic hyperplasia. 3) A multidisciplinary approach is essential for optimal management. Recent guidelines and the pivotal MGTX trial have reinforced the role of thymectomy in MG patients with thymic hyperplasia, demonstrating benefits in reducing symptom severity and in long-term remission rates.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with resected breast CA and received radiotherapy developed horner syn and plexopathy, what is the underlying mechanism",
    "option_a": "Compressive (not sure)",
    "option_b": "radiation induced",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "In patients who have undergone treatment for breast cancer with radiotherapy, late-onset neurological complications may occur. Radiation-induced nerve injury is a well-documented phenomenon that can affect both the brachial plexus and the sympathetic chain, potentially leading to conditions such as brachial plexopathy and Horner syndrome. Radiation can cause fibrosis, demyelination, and direct damage to nerves. The resulting damage may manifest as a plexopathy with gradual onset of pain, muscle weakness, and sensory deficits. When the radiation field encompasses regions near the cervical sympathetic chain, Horner syndrome (ptosis, miosis, anhidrosis) can develop. This patient\u2019s history of breast cancer, subsequent radiotherapy, and the development of both a plexopathy and Horner syndrome are highly suggestive of a radiation-induced mechanism rather than a compressive lesion from tumor recurrence. The insidious onset following radiotherapy is typical for radiation-induced neuropathies. The workup includes imaging studies such as MRI to evaluate for radiation-induced changes versus a compressive mass (which would typically show focal enhancement). Electrophysiological studies (EMG/NCS) can further characterize the pattern of nerve injury. Differential diagnoses include tumor recurrence with compressive effects, inflammatory neuropathies, and other iatrogenic injuries. Management is largely supportive, focusing on physical therapy, pain control, and occupational therapy. There is no definitive cure for radiation-induced neuropathy. In pregnant or lactating patients, it must be emphasized that radiotherapy is contraindicated, and special care is taken to mitigate long-term neurologic side effects in women of childbearing potential. Option A (compressive) would be more indicative of a mass effect typically seen with tumor recurrence; however, the clinical scenario (post-radiotherapy status with delayed onset of symptoms) strongly favors a radiation-induced etiology. Therefore, Option B (radiation induced) is the correct underlying mechanism. 1) Radiation-induced brachial plexopathy often presents months to years after treatment and lacks the focal mass effect seen with tumor recurrence. 2) The association of Horner syndrome with plexopathy in a post-radiotherapy patient is highly suggestive of radiation injury. 3) MRI and clinical history are critical in distinguishing radiation-induced pathology from compressive lesions. Recent research has focused on the characteristic MRI findings\u2014diffuse, non-enhancing, T2 hyperintense changes\u2014in radiation-induced brachial plexopathy, providing a differentiation from neoplastic compression. Guidelines stress the importance of long-term follow-up for patients receiving radiotherapy.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt smoker attached xray w lung tumor?? Has peripheral neuropathy, Asking about the cause?",
    "option_a": "Paraneoplastic",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Paraneoplastic syndromes are remote effects of cancer caused by an immune response triggered by tumor antigens. In lung cancer, particularly small cell carcinoma, paraneoplastic neurological syndromes, including peripheral neuropathy, are well documented. The immune system, in its attempt to target tumor antigens, may produce antibodies (e.g., anti-Hu antibodies) that cross-react with neuronal tissue, leading to peripheral nerve injury. This autoimmune process results in a paraneoplastic peripheral neuropathy. A smoker presenting with a lung mass on imaging and peripheral neuropathy raises strong clinical suspicion for a paraneoplastic syndrome. The pattern of neuropathy is typically multifocal and may precede the diagnosis of the underlying malignancy. The evaluation includes nerve conduction studies, electromyography, and serologic tests for paraneoplastic antibodies (such as anti-Hu). Differential diagnoses include direct tumor compression, chemotherapy-induced neuropathy, and metabolic causes (e.g., diabetic neuropathy), which can be differentiated by history, timing, and additional laboratory/imaging studies. The primary management is aimed at treating the underlying lung cancer. Immunotherapy (e.g., corticosteroids, IVIG, or plasmapheresis) can be considered to mitigate the immune-mediated nerve damage. In pregnant patients, treatment is challenging; the risks and benefits of immunomodulatory treatments and cancer therapies must be carefully balanced, often requiring a multidisciplinary team approach. Lactation considerations also involve tailoring therapy to minimize neonatal exposure to harmful agents. Option A (paraneoplastic) is correct, as the patient's clinical scenario of a lung tumor in a smoker with peripheral neuropathy strongly supports an immune-mediated paraneoplastic process. Other potential causes such as compressive lesions or toxic neuropathies are less consistent with the overall clinical picture. 1) Paraneoplastic neuropathies can precede the diagnosis of lung cancer and should prompt a search for an occult malignancy. 2) The presence of anti-neuronal antibodies (such as anti-Hu) is supportive of the diagnosis. 3) Early diagnosis and treatment of the underlying cancer are crucial to managing paraneoplastic neurological syndromes. Emerging research into paraneoplastic syndromes continues to refine antibody panels and immunotherapeutic strategies. Current guidelines emphasize the importance of a multidisciplinary approach for optimal management, as early treatment of the malignancy can sometimes stabilize or even improve neurological symptoms.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Case of duchenne w gower signb and calf hypertrophy asked about how to dx?",
    "option_a": "Muscle biopsy\u2026",
    "option_b": "CK level",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Duchenne muscular dystrophy (DMD) is an X\u2010linked recessive disorder characterized by progressive proximal muscle weakness, with hallmark signs such as the Gower maneuver and calf pseudohypertrophy. DMD is caused by mutations in the dystrophin gene. The absence or dysfunction of dystrophin leads to instability of the muscle fiber membrane, resulting in repeated cycles of muscle damage and repair. This results in muscle fiber necrosis, fibrosis, and eventual replacement by fat and connective tissue. Elevated serum creatine kinase (CK) levels are due to leakage from damaged muscle fibers. Patients typically present in early childhood with difficulty in rising from the floor (using the Gower maneuver), waddling gait, and calf pseudohypertrophy. The markedly elevated CK levels (often 10\u2013100 times normal) are a key laboratory finding supporting the diagnosis. The initial diagnostic test is to check the serum CK level, which is non\u2010invasive and highly sensitive. Although muscle biopsy and genetic testing (e.g., multiplex PCR or MLPA for deletions/duplications) are definitive, CK serves as an effective screening tool. Differential diagnoses include Becker muscular dystrophy and other myopathies, which can be differentiated based on age of onset, progression, and genetic testing. There is no cure, and management is supportive. First-line strategies include corticosteroids (e.g., prednisone) to slow disease progression, physical therapy to maintain mobility, and orthopedic interventions for contractures. Recent guidelines emphasize the role of multidisciplinary care. In pregnancy or lactation, corticosteroid regimens should be carefully managed to balance maternal benefits with potential risks to the fetus or nursing infant. Option A (Muscle biopsy) is an invasive method that can provide definitive histological evidence but is usually reserved for when genetic testing is inconclusive or not available. Option B (CK level) is correct as it is the simplest, quickest, and least invasive initial test used to support the diagnosis in a suspected case of DMD. Options C and D are not provided or relevant in this context. 1. The Gower sign is pathognomonic for proximal muscle weakness as seen in DMD. 2. Calf pseudohypertrophy is due to fat and connective tissue replacement rather than true muscle hypertrophy. 3. Markedly elevated CK levels in a young boy with these signs should prompt further genetic testing. Recent guidelines emphasize early screening using serum CK and genetic testing for timely diagnosis. Advances in molecular therapy and gene-based interventions are under investigation, although current management remains largely supportive.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with high CK and myositis, on statin",
    "option_a": "Stop statin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Statin-associated myopathy encompasses a spectrum of muscle-related symptoms and laboratory abnormalities that can occur in patients using statin medications. It is one of the most common drug-induced myopathies. Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol synthesis. In susceptible individuals, this inhibition can lead to decreased production of isoprenoids and coenzyme Q10, impairing mitochondrial function in muscle cells. This disturbance can cause muscle fiber injury leading to myalgia, weakness, and elevated CK levels. In rare instances, an immune-mediated necrotizing myopathy can occur that does not resolve with mere discontinuation. Patients typically complain of muscle pain, weakness, and tenderness sometimes associated with dark urine (if rhabdomyolysis occurs). The laboratory finding of an elevated CK level suggests muscle injury. In the setting of a statin use history, these findings are highly suggestive of statin-induced myopathy. Diagnosis starts with a detailed medication history and physical exam; serum CK levels are essential. Differential diagnoses include polymyositis and other inflammatory myopathies; however, the temporal correlation with statin initiation and improvement upon discontinuation favor statin-induced myopathy. Electromyography and muscle biopsy may be used if symptoms persist or if an autoimmune process is suspected. The first line management is to discontinue the statin to assess for resolution of symptoms and normalization of CK levels. In cases of mild myalgia with modest CK elevations, re-challenging with a lower dose or an alternative statin might be attempted once symptoms resolve. In suspected autoimmune myopathy, further immunological workup and therapy with corticosteroids may be indicated. During pregnancy and lactation, statins are contraindicated, so alternative lipid management strategies should be employed. Option A (Stop statin) is the correct initial step in managing a patient presenting with high CK levels and myositis in the setting of statin therapy. The other options, which are not shown, would likely include non-intervention or continuation strategies that are not appropriate in the presence of statin-induced myopathy. 1. Always correlate statin use with new onset muscle pain and elevated CK levels. 2. Most cases resolve with discontinuation of the drug. 3. Consider autoimmune myopathy if symptoms and CK elevation persist after statin withdrawal. Recent research supports an initial conservative management of statin-induced myopathy with cessation of the drug. Current guidelines emphasize monitoring in patients with risk factors and advocate for alternative lipid-lowering therapies in patients who develop significant myopathy.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient has right hand pain, left leg pain, absent brachioradialis tendon, absent bilateral knee reflexes (high ESR)",
    "option_a": "Mononeuritis multiplex",
    "option_b": "mono neuropathy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Mononeuritis multiplex is a form of peripheral neuropathy where two or more separate nerve areas are affected in an asymmetric, non-length-dependent pattern often due to an inflammatory process such as vasculitis. It typically results from inflammation of the vasa nervorum, the small blood vessels that supply peripheral nerves. This leads to ischemia and subsequent axonal injury. The process is commonly seen in systemic conditions like rheumatoid arthritis, systemic lupus erythematosus, or primary vasculitides, and is associated with systemic inflammatory markers such as an elevated ESR. Clinically, patients present with asymmetric pain, weakness, and sensory loss in the distribution of individual nerves. In the presented case, right hand pain and left leg pain, along with absent deep tendon reflexes (like the brachioradialis and knee reflexes), align with a multifocal nerve involvement rather than a single nerve. Diagnosis involves a detailed clinical history, neurological examination, and electrodiagnostic studies (nerve conduction studies and electromyography). Differential diagnoses include conditions like diabetic polyneuropathy (which is usually symmetric), radiculopathy, or a focal neuropathy from compression. The pattern of patchy involvement combined with high inflammatory markers points towards an inflammatory or vasculitic process. Management is highly etiology-dependent. In vasculitic or immune-mediated cases, first-line treatment involves immunosuppressive therapy (e.g., corticosteroids). Additional immunomodulatory agents such as cyclophosphamide or methotrexate may be considered in refractory cases. In pregnancy or lactation, corticosteroids are generally considered safe at appropriate doses, but other immunosuppressants require careful risk-benefit analysis and consultation with specialists. Option A (Mononeuritis multiplex) is correct because the clinical presentation (asymmetric pain distribution, absent reflexes in multiple regions, and elevated ESR) strongly supports a multifocal inflammatory neuropathy. Option B (mono neuropathy) is incorrect as it implies a single nerve involvement, which does not account for the bilateral and patchy deficits observed. 1. An elevated ESR with focal neurological deficits should raise suspicion for a vasculitic process. 2. The asymmetric pattern of deficits is a key distinguishing feature of mononeuritis multiplex compared to more symmetric polyneuropathies. 3. Early recognition and treatment of the underlying inflammatory process are critical to prevent permanent nerve damage. Recent studies underscore the importance of early diagnosis and treatment of underlying systemic inflammatory diseases. Updated guidelines advocate for prompt initiation of immunosuppressive therapy in cases of vasculitis-associated mononeuritis multiplex to reduce morbidity.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Cmt1 HMSAN 1:",
    "option_a": "PMP 22 duplication",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Charcot-Marie-Tooth disease (CMT) is a hereditary peripheral neuropathy characterized by progressive distal muscle weakness, atrophy, and sensory loss. CMT1, the demyelinating form, is the most common, and CMT1A in particular is typically due to a duplication of the PMP22 gene. In CMT1A, duplication of the PMP22 gene leads to overexpression of a myelin protein in peripheral nerves. This disrupts normal myelin formation resulting in demyelination, slowed nerve conduction velocities, and secondary axonal loss. The clinical phenotype includes foot deformities (such as pes cavus), distal muscle weakness, and sensory deficits. Patients with CMT1 usually present in childhood or early adulthood. They often have feet deformities, gait abnormalities, and distal muscle wasting. The disease gradually progresses, although most patients maintain ambulation throughout life. Diagnosis is based on clinical examination, nerve conduction studies showing uniform demyelination, and genetic testing confirming PMP22 duplication in CMT1A. Differential diagnoses include other hereditary neuropathies (like CMT2 which is axonal) and acquired demyelinating polyneuropathies, which are differentiated based on electrophysiological studies and genetic workup. There is no cure for CMT; management is supportive. First-line interventions include physical therapy, orthotic devices, and occupational therapy to maximize function and prevent contractures. Surgical interventions may address severe foot deformities. Genetic counseling is recommended. In pregnancy and lactation, management remains supportive with emphasis on maintaining mobility and monitoring for any complications related to orthopedic issues. Option A (PMP22 duplication) is correct because it directly identifies the genetic abnormality responsible for CMT1A, the most common form of CMT. The other options, though not specified, would likely involve alternative genetic defects not typically associated with CMT1. 1. Remember that CMT1A is typically due to a duplication of the PMP22 gene. 2. Nerve conduction studies in CMT1 show markedly slowed velocities due to demyelination. 3. The clinical picture of foot deformities, distal muscle wasting, and sensory loss in a young patient is highly suggestive of CMT. Current research continues to explore gene therapy and targeted molecular treatments for CMT. However, the mainstay of management remains supportive care with a multidisciplinary approach. Updated guidelines stress the importance of genetic counseling and orthopedic management in these patients.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Female smoker with sensory neuropathy and motor symptoms chest xray attached showed mass at lung apex what is dx",
    "option_a": "Parneoplastic",
    "option_b": "Antibody",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a female smoker with a lung apex mass on chest imaging and concurrent sensorimotor neuropathy. Such a constellation of findings is characteristic of a paraneoplastic neurological syndrome, where a malignancy (often lung cancer) triggers an immune response affecting the nervous system. Paraneoplastic neurological syndromes arise when tumor cells express neural antigens. The immune system produces auto\u2010antibodies (commonly anti\u2010Hu among others) that mistakenly target neural tissues, causing both sensory and motor deficits. This immune\u2010mediated neuronal injury occurs independent of any direct tumor compression. In a smoker with an apical lung mass\u2014often seen in Pancoast tumors\u2014and with symptoms affecting both sensation and motor function, a paraneoplastic syndrome should be high on the differential. These syndromes typically develop subacutely and can precede the formal diagnosis of cancer. Evaluation includes detailed history and neurological examination, chest imaging (CT/MRI) to characterize the lung mass, and serologic testing for onconeural antibodies (eg, anti\u2010Hu). Differential diagnoses include direct nerve compression by a Pancoast tumor (which may more classically involve Horner\u2019s syndrome) and non\u2010paraneoplastic peripheral neuropathies. The cornerstone of management is treating the underlying malignancy. Immunotherapy (eg, high\u2010dose steroids, IVIg, or plasmapheresis) may be considered to dampen the autoimmune response. In patients who are pregnant or lactating, treatment plans must be modified: for instance, selecting chemotherapy regimens with lower teratogenic risks and using the lowest effective doses of immunomodulators while carefully balancing maternal\u2013fetal risks. Option A (Paraneoplastic) correctly identifies the syndrome as a paraneoplastic neurological syndrome. Option B (Antibody) is imprecise, as it refers to the lab marker (eg, anti\u2010Hu) rather than the clinical diagnosis. Options C and D are either missing or non\u2010informative. Thus, the best answer is A. 1. In smokers with an apex lung mass and sensorimotor deficits, always consider a paraneoplastic syndrome. 2. Anti\u2010Hu antibodies are frequently associated with paraneoplastic neuropathies related to lung cancer. 3. Early recognition can lead to more timely oncologic and immunomodulatory interventions. Recent studies emphasize the importance of early detection of paraneoplastic syndromes via comprehensive antibody panels and imaging. Newer immunotherapeutic strategies are under investigation to modulate the immune response, and multidisciplinary approaches have been shown to improve both neurological and oncological outcomes.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Female smoker with sensory neuropathy and motor symptoms chest xray attached showed mass at lung apex what is abx",
    "option_a": "Anti hu",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "In patients with lung cancer and paraneoplastic neurological syndromes, specific auto-antibodies provide important diagnostic clues. In this case, the antibody being queried is one frequently associated with such syndromes. Anti\u2010Hu antibodies (also known as ANNA-1) are produced when the immune system reacts against tumor antigens that share similarity with neuronal proteins. This immune cross-reactivity causes damage to peripheral neurons, leading to sensorimotor deficits. A female smoker presenting with a lung apex mass and subacute sensorimotor neuropathy is classically seen in paraneoplastic syndromes linked to small cell lung cancer. The detection of anti\u2010Hu antibodies reinforces the diagnosis and helps to differentiate it from other neuropathies. The work-up involves chest imaging to assess the lung mass, clinical evaluation of the neuropathy, and serological testing for anti\u2010Hu antibodies. Differential diagnoses include direct compressive neuropathies and other autoimmune neuropathies; antibody testing helps narrow the diagnosis. Management is twofold\u2014treat the underlying lung cancer and use immunomodulatory therapies (such as high\u2010dose steroids, IVIg, or plasmapheresis) to control the immune-mediated damage. In pregnancy, care is taken to select therapy that minimizes fetal exposure; for example, certain immunosuppressants and chemotherapeutic agents are avoided or used at adjusted doses. Option A (Anti Hu) is correct because it identifies the specific antibody linked to the paraneoplastic neuropathy in this clinical setting. Other options are either not provided or not relevant to the antibody in question. 1. Anti\u2010Hu antibodies are a key marker for paraneoplastic neuropathies typically seen in association with lung cancer. 2. Always correlate serologic findings with clinical and imaging data. 3. Early detection can significantly influence management strategies. Recent guidelines underscore the role of comprehensive antibody panels in diagnosing paraneoplastic syndromes. Moreover, emerging immunotherapeutic strategies are increasingly being incorporated into treatment protocols, with ongoing research focusing on improving neurological outcomes.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Breast Ca case post resection, chemoradiation therapy. Having arm pain. NCS showed evidence of lower plexopathy. What is the most likely cause?",
    "option_a": "Compression",
    "option_b": "Radiation",
    "option_c": "Infiltrating plexopathy?",
    "option_d": "Contiuum Q",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Post-treatment breast cancer patients can develop brachial plexopathy due to various causes. Two common etiologies are radiation-induced injury and neoplastic infiltration (ie, tumor recurrence invading the plexus). Infiltrative or neoplastic brachial plexopathy occurs when recurrent tumor cells invade the nerve network, causing inflammation, pain, and subsequent nerve conduction disturbances. In contrast, radiation-induced plexopathy results from progressive fibrosis and demyelination secondary to radiation exposure, and typically exhibits a different clinical pattern. This patient presents with significant arm pain and nerve conduction studies showing lower plexus (C8-T1) involvement. Notably, neoplastic infiltration tends to affect the lower plexus and is associated with severe pain, whereas radiation-induced plexopathy more often involves the upper plexus and is usually less painful. Differentiation involves imaging studies\u2014especially MRI of the brachial plexus\u2014to identify structural abnormalities. Nerve conduction studies can support the diagnosis, and the clinical timeline along with symptom severity (severe pain often pointing to recurrence) helps in distinguishing between the two. Other differentials include postoperative nerve damage and compressive neuropathies from scar tissue. For infiltrative brachial plexopathy due to tumor recurrence, management typically includes oncologic treatments such as surgery, chemotherapy, or additional radiotherapy tailored to the patient\u2019s overall status. Pain management and physical rehabilitation are supportive pillars. In pregnant or lactating patients, management should be multidisciplinary with careful consideration of fetal exposure to chemotherapeutic agents and radiation; alternative therapies or timing adjustments may be needed. Option C (Infiltrating plexopathy) is the best fit given the severe arm pain and lower plexus involvement. Option A (Compression) is less likely without evidence of an external mass compressing the nerves. Option B (Radiation) tends to present with milder pain and more upper plexus involvement. Option D is ambiguous and non-informative. 1. In breast cancer survivors, severe arm pain with lower plexus involvement should raise suspicion for neoplastic recurrence rather than radiation injury. 2. Imaging with MRI is essential to differentiate between infiltration and post-radiation fibrosis. 3. Early identification of tumor recurrence can significantly alter the management and prognosis. Recent studies have highlighted the differing patterns of plexopathy post-breast cancer treatment. Advanced imaging techniques combined with electrophysiological studies have improved the differentiation between radiation-induced and neoplastic brachial plexopathy, guiding more targeted therapeutic approaches.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with polymyalgia rheumatica on steroid 5 mg post MI and HTN on atorvastatin 40 pw proximal muscle weakness cannot rise from seat position with pain. Ck 1880. Diagnosis?",
    "option_a": "Steroid myopathy",
    "option_b": "Statin myopathy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Patients with proximal muscle weakness can have multiple etiologies. In the setting of statin use and concurrent muscle pain with elevated creatine kinase (CK), statin-induced myopathy is a strong consideration. This contrasts with steroid myopathy, which typically presents with painless weakness and normal CK levels. Statin myopathy is thought to result from disruptions in muscle cell membrane integrity, mitochondrial dysfunction, and apoptosis due to altered cholesterol synthesis pathways, leading to myocyte injury and consequent CK elevation. By contrast, steroid myopathy is usually due to catabolic effects on muscle fibers from high-dose corticosteroids, and it generally does not cause muscle pain or CK elevation. This patient, on atorvastatin 40 mg, presents with proximal muscle weakness (difficulty rising from a seated position) accompanied by pain and a significantly elevated CK (1880 U/L). This pattern aligns with statin-induced myopathy rather than steroid-induced myopathy, which is usually painless and has normal CK values. The differential diagnosis includes inflammatory myopathies, statin-induced myopathy, and steroid myopathy. A detailed medication review, clinical history, physical examination, and laboratory testing including CK levels help distinguish these conditions. Electromyography (EMG) and sometimes muscle biopsy can be considered if the diagnosis remains uncertain. The first step in managing statin-induced myopathy is the reduction or discontinuation of the offending statin, with close monitoring of muscle symptoms and CK levels. Switching to a different statin at a lower dose or to alternative lipid-lowering therapies may be needed. Supportive care with hydration and rest is also beneficial. For patients who are pregnant or lactating, statins are contraindicated due to their teratogenic potential; alternative lipid-lowering strategies, such as bile acid sequestrants, should be considered. Option B (Statin myopathy) is correct given the clinical findings of muscle pain, weakness, and elevated CK. Option A (Steroid myopathy) is less likely because steroid-induced weakness is typically painless with normal CK levels. Options C and D are not provided or relevant in this context. 1. Always check CK levels in patients on statins presenting with muscle pain and weakness. 2. Steroid myopathy generally presents as a painless weakness with normal CK levels. 3. Early recognition and modification of the offending agent are key to preventing severe complications such as rhabdomyolysis. Recent research has focused on identifying genetic predispositions for statin-induced myopathy and developing guidelines for statin dose adjustments. Updated recommendations emphasize monitoring for muscle symptoms and CK levels, and in cases where statin therapy is essential, switching agents or dosing adjustments are supported as best practice.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with polymyalgia rheumatica on steroid 5 mg post MI and HTN on atorvastatin 40 pw proximal muscle weakness cannot rise from seat position with pain. Ck 1880. Next step?",
    "option_a": "Stop steroid",
    "option_b": "Stop atorvastatin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This case illustrates a drug\u2010induced myopathy occurring in a patient on multiple medications. Although the patient is on steroids for polymyalgia rheumatica, the clinical picture (proximal muscle weakness with pain, difficulty rising from a chair, and a markedly elevated CK of 1880) is more typical of statin-induced myopathy rather than steroid myopathy. Statin-induced myopathy is believed to result from several mechanisms, including impaired mitochondrial function (via reduction of coenzyme Q10), altered cellular energy metabolism, and direct toxic effects on muscle fibers. In contrast, steroid myopathy, especially from low-dose steroids, typically causes painless proximal weakness with normal CK levels. Patients with statin-induced myopathy often present with muscle pain and weakness, particularly in the proximal muscle groups. The presence of muscle pain and a significant CK elevation differentiates it from steroid myopathy where weakness is usually painless and CK remains normal. The workup should include a thorough medication history, serum CK measurement, and possibly electromyography if diagnostic uncertainty persists. Differential diagnoses include polymyositis (typically with inflammatory markers and biopsy findings), hypothyroid myopathy (associated with thyroid function abnormalities), and other drug-induced myopathies. Stopping the statin is both diagnostic and therapeutic if symptoms improve. First-line management is to discontinue the offending agent (atorvastatin). In most cases, this leads to clinical and biochemical improvement. Rechallenge or switching to a different statin at a lower dose can be considered later if indicated. In cases of severe toxicity or rhabdomyolysis, hospitalization and aggressive hydration may be required. For patients who are pregnant or lactating, statins are contraindicated because of teratogenic potential; alternative lipid-lowering strategies must be considered. Option A (Stop steroid) is incorrect because the low-dose steroid is less likely the culprit (steroid myopathy usually presents with painless weakness and normal CK), whereas Option B (Stop atorvastatin) addresses the likely cause. Options C and D are not provided and hence not applicable. 1. Statin-induced myopathy typically presents with proximal muscle pain/weakness and elevated CK. 2. Steroid myopathy, in contrast, is generally painless with normal CK levels. Recent guidelines emphasize a careful review of medications in patients with myopathic symptoms. The American College of Cardiology recommends discontinuing the statin in symptomatic patients with significant CK elevation, with a systematic reintroduction plan if necessary.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Case of young boy 14 years old wih gi symptoms came with feature of GBS csf high prot what is mx",
    "option_a": "IVIG",
    "option_b": "steroid",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question describes a classic presentation of Guillain\u2013Barr\u00e9 syndrome (GBS), an acute paralytic neuropathy that most often follows an infectious illness. GBS is an immune-mediated demyelinating disorder of peripheral nerves, most commonly triggered by an antecedent gastrointestinal or respiratory infection. The immune response cross-reacts with nerve antigens, leading to segmental demyelination and, in some subtypes, axonal injury. Patients often present with ascending weakness, areflexia, and occasionally respiratory compromise. A hallmark is albuminocytologic dissociation (elevated CSF protein with normal cell count) as seen in this patient. Differential diagnoses include acute transverse myelitis, tick paralysis, and myasthenia gravis. CSF analysis (showing high protein with normal cell count) and nerve conduction studies (demonstrating slowed conduction velocities) help confirm the diagnosis of GBS. First-line treatment for GBS is intravenous immunoglobulin (IVIG), particularly in pediatric patients, as it is easier to administer and has a favorable safety profile compared to plasma exchange. Plasma exchange is an alternative option. Steroids have not proven effective in altering the disease course. In pregnancy, both IVIG and plasma exchange are considered relatively safe when managed carefully. Option A (IVIG) is correct as it is the established first-line treatment in children with GBS. Option B (steroids) is incorrect because clinical trials have not demonstrated benefit in GBS. Options C and D are not provided. 1. GBS classically follows a gastrointestinal or respiratory infection and features an elevated CSF protein with normal white cell count. 2. IVIG is the preferred treatment in pediatric cases and in pregnancy due to its safety profile. Recent guidelines from neurology societies continue to support the use of IVIG as first-line therapy for GBS, noting similar efficacy compared to plasma exchange. Ongoing studies are aimed at optimizing dosing and timing of therapy.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Same question what is the bipsy finding same this pic in exam",
    "option_a": "antitubular",
    "option_b": "Myophospherlase",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question appears to target a metabolic myopathy where muscle biopsy is used to detect enzyme deficiencies. In particular, the mention of myophosphorylase aligns with McArdle disease (glycogen storage disease type V). McArdle disease is caused by a deficiency of myophosphorylase, an enzyme essential for the breakdown of glycogen in muscle. The enzyme deficiency leads to an energy crisis during exercise, resulting in muscle damage, pain, and sometimes rhabdomyolysis. Clinically, patients present with exercise intolerance, muscle cramps, and sometimes myoglobinuria following strenuous activity. The classic finding is a second-wind phenomenon, where symptoms improve with continued low-intensity exercise due to alternative energy utilization. Besides the clinical history, diagnostic studies include the ischemic forearm exercise test (which shows a flat lactate curve), genetic testing, and muscle biopsy. On biopsy, a lack of myophosphorylase activity (demonstrated by histochemical staining) confirms the diagnosis. Differential diagnoses include other metabolic myopathies (like mitochondrial myopathy) and inflammatory myopathies, which have different clinical and histologic features. Management is primarily supportive. Patients are advised to avoid strenuous exercise and may benefit from a moderate aerobic exercise program. A high-carbohydrate diet and pre-exercise ingestion of simple sugars can help mitigate symptoms. There is no definitive curative treatment as the defect is genetic. In pregnancy and lactation, dietary modifications remain the cornerstone of management, and exercise recommendations are tailored to individual tolerance. Option B (Myophospherlase) is correct because the biopsy in McArdle disease demonstrates absent or markedly reduced myophosphorylase activity. Option A ('antitubular') is not a recognized finding in this context, and the other options are either missing or irrelevant. 1. McArdle disease should be suspected in patients with exercise-induced cramps and episodes of myoglobinuria. 2. The absence of myophosphorylase activity on muscle biopsy is diagnostic for this condition. Recent advances have focused on improved genetic diagnosis for McArdle disease. Although there is ongoing research into enzyme replacement and gene therapies, current management remains supportive with an emphasis on dietary and exercise modifications.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Case of patient with chocicine toxity induced myopathy with high CK and EMG prominent fibrillations, positive sharp waves and excessively polyphasic motor action potentials in the proximal muscles that are brief and small in amplitude, what is the cause",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Neuromuscular",
    "explanation": "This question describes a toxic myopathy induced by colchicine toxicity. The clinical presentation\u2014elevated CK, proximal muscle weakness, and specific EMG findings (fibrillations, positive sharp waves, and small, brief polyphasic motor unit potentials)\u2014points to a toxic, rather than a primary inflammatory or degenerative, myopathy. Colchicine impairs microtubule polymerization which disrupts intracellular transport and mitosis. In muscle tissue, this results in vacuolar changes and myofiber damage, leading to a toxic myopathy. This toxicity is often dose-related or related to impaired clearance in patients with renal dysfunction. Patients with colchicine-induced myopathy present with proximal muscle weakness and often have an elevated CK. The EMG findings of small, brief polyphasic motor units with fibrillations and positive sharp waves are characteristic of myopathic rather than neuropathic processes. These features help distinguish it from inflammatory myopathies, neuropathies, muscular dystrophies, and metabolic myopathies. The diagnosis hinges on a careful medication history (noting exposure to colchicine), clinical examination, CK levels, and EMG studies. Differential diagnoses include inflammatory myopathy (which would show inflammatory infiltrates on biopsy), neuropathy (characterized by denervation potentials and reinnervation changes), muscular dystrophy (a genetic and progressive disorder with distinct biopsy findings), and metabolic myopathy (which typically has exercise-induced symptoms with specific enzyme deficiencies). Electromyography and muscle biopsy (if performed) confirm the toxic nature without the hallmarks of inflammation or genetic dystrophy. The cornerstone of management is discontinuation of colchicine. Supportive care includes monitoring CK levels and symptomatic treatment with physical therapy if needed. In severe cases, hospitalization might be required. For patients who are pregnant or lactating, colchicine is generally avoided due to potential toxicity \u2013 in fact, it is contraindicated in pregnancy for certain conditions, and its use requires careful risk\u2013benefit analysis. The provided options (inflammatory myopathy, neuropathy, muscular dystrophy, metabolic myopathy) do not correctly describe the cause of the EMG findings seen in colchicine toxicity. Each alternative option has features that do not align with the acute toxic process: (a) Inflammatory myopathy would have inflammatory infiltrates on biopsy and a different EMG pattern, (b) neuropathy has features related to denervation and reinnervation, (c) muscular dystrophy is chronic with genetic underpinnings, and (d) metabolic myopathy often presents with exercise intolerance and different enzyme deficiencies. As a result, none of the listed options is correct. 1. Colchicine toxicity should always be considered in patients on the drug who develop proximal muscle weakness with elevated CK levels. 2. EMG findings in toxic myopathies typically show small, brief polyphasic motor unit potentials along with fibrillations and positive sharp waves. Recent literature and case reports have reinforced the importance of recognizing colchicine-induced myopathy early. Current guidelines stress the need for medication review in patients presenting with myopathic symptoms, and the discontinuation of the offending agent is strongly recommended. Additionally, there is ongoing research into the mechanisms of drug-induced myopathies which may lead to improved diagnostic biomarkers in the future.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  }
]